An Open-label Study Assessing Safety, Immunogenicity and Dose Response of IC84

NCT01296386 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

82

Enrollment

INDUSTRY

Sponsor class

Conditions

Clostridium Difficile Infection

Interventions

BIOLOGICAL: IC84

Sponsor

Valneva Austria GmbH